WHO ICTRP trial
A randomized controlled trial for azacytidine combined with Standard induction…
ChiCTR1900023700 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1900023700 |
|---|---|
| Public title | A randomized controlled trial for azacytidine combined with Standard induction chemotherapy regimen (daunorubicin+cytarabine) in the treatment of adult acute myeloid leukemia / high risk myelodysplastic syndrome |
| Scientific title | A randomized controlled trial for azacytidine combined with Standard induction chemotherapy regimen (daunorubicin+cytarabine) in the treatment of adult acute myeloid leukemia / high risk myelodysplastic syndrome |
| Primary sponsor | West China Hospital, Sichuan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Acute myeloid leukemia/high risk myelodysplastic syndrome |
| Interventions | Experimental group:Azacitidine + daunorubicin + cytarabine;Control group:daunorubicin + cytarabine |
| Registration date | Jun 8, 2019 |
| Target size | Experimental group:50;Control group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: